Zenas BioPharma (ZBIO) announced that it has commenced underwritten public offerings of its convertible senior notes due 2032 and shares of its common stock. Jefferies, Evercore ISI, Citigroup and Guggenheim Securities are acting as joint book-running managers for the proposed convertible notes oOffering and proposed equity offering. Wedbush PacGrow is acting as co-manager for the proposed convertible notes offering and proposed equity offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBIO:
- Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis
- Zenas BioPharma price target raised to $55 from $45 at Guggenheim
- Balanced Near‑Term Outlook for Zenas BioPharma: Promising Obexelimab Pipeline and Strengthened Liquidity Offset by Commercial and Leverage Uncertainties
- Zenas BioPharma price target raised to $21 from $19 at Morgan Stanley
- Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target